Key result
Sulfinpyrazone cuts arteriovenous shunt thrombosis by ~67% compared to placebo.
RCT (n=45)
Double-blind
crossover
Answers are grounded in this paper and cite their sources.
The effect of sulfinpyrazone on the incidence of thrombosis of arterio-venous shunts was investigated in a double-blind crossover study in 45 patients on chronic hemodialysis over a period of 12 months. The incidence of thrombosis was reduced from 0.64 thrombi per patient month when on placebo to 0.21 thrombi per patient month when on sulfinpryazone (P less than 0.001). The therapeutic effect was more striking in men than in women and became evident within a week of starting the drug. The side effects were minimal, requiring withdrawal from the study of only one patient. This crossover study strengthens the findings in the previous report that sulfinpyrazone is of value in the prevention of thrombosis.
No takes yet. Share an insight, caveat, or question.
Kaegi et al. (1975) conducted an RCT in Chronic hemodialysis with arterio-venous shunts (n=45). Sulfinpyrazone vs. Placebo was evaluated on Incidence of thrombosis of arterio-venous shunts (p=<0.001). Sulfinpyrazone reduced the incidence of arterio-venous shunt thrombosis from 0.64 to 0.21 thrombi per patient month compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: